Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer

Cancer Biol Ther. 2004 Feb;3(2):205-6. doi: 10.4161/cbt.3.2.714. Epub 2004 Feb 1.

Authors

Kristine S Klos¹, Dihua Yu

Affiliation

¹ The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

PMID: 14764991
DOI: 10.4161/cbt.3.2.714

No abstract available

Publication types

Comment
Editorial

MeSH terms

Animals
Ascites / drug therapy*
Ascites / genetics
DNA-Binding Proteins / genetics
DNA-Binding Proteins / physiology
Disease Models, Animal
Female
Humans
Liposomes*
Mammary Neoplasms, Experimental / drug therapy*
Mammary Neoplasms, Experimental / metabolism
Mammary Neoplasms, Experimental / pathology
Mice
Mice, SCID
Nuclear Proteins
Oligonucleotides, Antisense / therapeutic use*
Receptor, ErbB-2 / antagonists & inhibitors
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism*
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Vascular Endothelial Growth Factor A / genetics
Vascular Endothelial Growth Factor A / pharmacokinetics*

Substances

DNA-Binding Proteins
Liposomes
Nuclear Proteins
Oligonucleotides, Antisense
RAG2 protein, human
Rag2 protein, mouse
V(D)J recombination activating protein 2
Vascular Endothelial Growth Factor A
Receptor, ErbB-2